US OptionsDetailed Quotes

XNCR241220C25000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 26 09:30 ET

0.00High0.00Low

Xencor Stock Discussion

Moomoo AI

Mar 10 07:41

Bassil Dahiyat's recent sale of Xencor shares is the largest insider sale in the past year. It's discouraging when insiders sell below the current price, suggesting satisfaction with a lower valuation. Despite insider ownership, caution is advised due to sales history.

Don't Ignore The Insider Selling In Xencor

Moomoo AI

Mar 7 05:47

Xencor's share price rise doesn't match its P/S ratio, likely due to weaker forecast growth than the industry. These conditions may continue to limit the share price.

Improved Revenues Required Before Xencor, Inc. (NASDAQ:XNCR) Stock's 27% Jump Looks Justified

Moomoo AI

Feb 5 13:56

Xencor's lack of profitability and uninspiring revenue growth, despite its pursuit of growth, may have led to its share price decline. Investors may question its long-term viability with continued weak revenue growth and unprofitability.

Xencor (NASDAQ:XNCR Shareholders Incur Further Losses as Stock Declines 8.5% This Week, Taking Three-year Losses to 65%

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2...

Moomoo AI

Dec 10, 2023 06:29

The consistent insider selling at Xencor could be a potential red flag, although it's worth noting that no insider trades have occurred recently. The company's relatively low insider ownership does not give much reassurance.

Possible Bearish Signals With Xencor Insiders Disposing Stock

Moomoo AI

Nov 13, 2023 20:45

Forecast changes hint at sales dwindling, with an expected revenue drop of 31% by end of 2024, a steep fall from 14% growth over the past five years. Xencor will likely trail in revenue growth compared to industry peers. These major downgrades might lead to a loss of market confidence in the company.

Bearish: Analysts Just Cut Their Xencor, Inc. (NASDAQ:XNCR) Revenue and EPS Estimates

Analysts Notebook

Jan 31, 2023 06:50

Columns US Top Rating Updates on 1/31: BAC, DLTR, EW, INCY and More

FibroGen Upgraded to Outperform at William Blair on Pamrevlumab's Potential
William Blair analyst Andy Hsieh upgraded $FibroGen (FGEN.US)$ to Outperform from Market Perform following a deep dive on the potential of pamrevlumab, the company's wholly owned monoclonal antibody against connective tissue growth factor, which is being evaluated in the treatment of idiopathic pulmonary fibrosis, or IPF, locally advanced pancreatic cancer, or LAP...

Peter Koh

Jun 1, 2022 13:12

$Xencor (XNCR.US)$ we need power

No comment yet